BETA
Your AI-Trained Oncology Knowledge Connection!
PFS, OS Improve With Cilta-Cel in R/R Multiple Myeloma Subgroups
Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.
Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma
PFS was improved with belantamab mafodotin triplet for patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.
Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer
Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.
Exploring Burnout Causes and Management in Oncologic Practice
Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.
Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC
A survival benefit was noted when elraglusib was added to chemotherapy for patients with metastatic PDAC.
Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses
Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.
Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma
The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.
Savolitinib Combo Prolongs PFS in Pretreated EGFR+ NSCLC
Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.
HER3-DXd Does Not Yield Improved OS in EGFR-Mutated NSCLC
Results from HERTHENA-Lung02 did not show improved OS with HER3-DXd for patients with EGFR-mutated NSCLC.
39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction
Sevabertinib Exhibits Activity in Treatment-Naïve HER2-Mutant NSCLC
Among 2 patient subgroups with advanced, HER2-mutant non–small cell lung cancer, sevabertinib showed comparable objective response rates.
Glofitamab Combo Boosts Survival vs Rituximab in Relapsed/Refractory DLBCL
The safety profile for glofitamab plus gemcitabine and oxaliplatin in diffuse large B-cell lymphoma was consistent with known risks for individual drugs.
Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC
Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.
Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Sintilimab/Chidamide Combo Shows Activity in Early-Stage ENKTL
At a median follow-up of 17.0 months, the sintilimab/chidamide regimen elicited 1-year PFS and OS rates of 95.7% and 95.3%, respectively.
Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets
The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.
Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma
Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.
Data Show Low Severity AEs With Liso-Cel Across Blood Cancer Settings
Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.
Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC
Cisplatin, nab-paclitaxel, gemcitabine, and capecitabine significantly improved EFS vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.
Adagrasib/Pembrolizumab Yields Improved Survival in KRAS G12C-Mutated NSCLC
Results from the KRYSTAL-7 trial showed that efficacy was improved with adagrasib/pembrolizumab for KRAS G12C-mutated NSCLC.
Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer
Five-year follow-up confirms adjuvant nivolumab's sustained disease-free and distant metastasis-free survival benefits in resected esophageal/GEJ cancer post-CRT.
NAPOLI-3 Post Hoc Review Highlights Long-Term Survival With NALIRIFOX in PDAC
A post hoc analysis of NAPOLI-3 reveals clinical characteristics and treatment strategies associated with long-term survival in patients with metastatic PDAC treated with NALIRIFOX.
Fruquintinib Combo Exhibits Frontline Efficacy in Advanced ESCC
No fatalities were observed with fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin when treating esophageal squamous cell carcinoma.
Recurrence or Risk of Death Reduced by 50% With Atezolizumab/Chemo in dMMR Colon Cancer
Results from the ATOMIC trial found a 50% reduction in the risk of death for patients with dMMR colon cancer receiving atezolizumab/chemotherapy.
Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer
Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.
Durvalumab Regimen Extends EFS in Resectable Gastric/GEJ Adenocarcinoma
Data from the MATTERHORN trial may be “practice-changing” in the management of resectable gastric or gastroesophageal junction adenocarcinoma.
Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer
Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.
Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer
Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.
T-DXd Yields PFS Across Mutation Subtypes for HR+, HER2-low Breast Cancer
In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.
Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm
Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.
